NanoSyrinx announces closure of its Pre-Seed investment round
The team at NanoSyrinx are delighted to announce our pre-seed financing with an excellent board of investors: MVentures, BioCity and UKI2S.
Our seed round is helping us deliver key scientific milestones as we look to create a revolution in the delivery of biologic molecules in the cell and gene therapy and conventional therapeutic space.
NanoSyrinx is now preparing for its next full seed raise Q4-2020/Q1-2021, so if you’d like to be involved in the next round and join us on our journey, please get in touch!
Full press release details can be found here:
https://www.sciadnewswire.com/news/604/synthetic-biology-start-nanosyrinx-secures-capital-develop-its-fully-customisable-platform
Follow us on social media to stay up to date!
@NanoSyrinx
https://www.linkedin.com/company/nanosyrinx
